NUVBNYSEPharmaceutical PreparationsFiscal year ends December 31
Nuvation Bio Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$4.48+0.03 (+0.67%)
Close on Oct 19, 2026
- Market cap
- $1.56M
- P/E (TTM)
- –
- Dividend yield
- –
Nuvation Bio Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| License [Member] | $104.77M | $99.87M | $38.24M | $17.79M | $13.12M | $10.96M | $7.87M | 61.7% | +698.8% |
| Product [Member] | $65.13M | $43.17M | $24.66M | $8.96M | $1.24M | $0 | $0 | 38.3% | +5160.7% |
| Product Revenue [Member] | $65.10M | $42.32M | $24.70M | – | – | – | – | 38.3% | – |
| Research And Development Service Revenue [Member] | – | – | – | – | – | $7.84M | $5.79M | – | – |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| United States | $124.01M | $102.05M | $24.66M | $8.96M | $1.24M | – | $0 | 73.0% | +9916.6% |
| Japan | $29.56M | $29.30M | $28.83M | $5.36M | $2.81M | $2.91M | $2.73M | 17.4% | +952.0% |
| China | $16.34M | $11.70M | $9.41M | $12.43M | $10.31M | $8.05M | $5.15M | 9.6% | +58.5% |
From the segment and revenue-disaggregation notes of Nuvation Bio's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.